Protein kinase D as a potential new target for cancer therapy

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1806, Issue 2, 2010, Pages 183-192

  LaValle, Courtney R ^a   George, Kara M ^b   Sharlow, Elizabeth R ^a,b   Lazo, John S ^a,b   Wipf, Peter ^b   Wang, Q Jane ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer; Protein kinase D; Small molecule inhibitors

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 [1 (3 DIMETHYLAMINOPROPYL) 5 METHOXY 1H INDOL 3 YL] 3 (1H INDOL 3 YL)MALEIMIDE; ANTINEOPLASTIC AGENT; BENZAMIDINE DERIVATIVE; BISINDOLYLMALEIMIDE I; BISINDOLYLMALEIMIDE II; CID 755673; CRT 0066101; HISTONE DEACETYLASE; K 252A; KB NB 142 02; KB NB 142 09; KB NB 142 31; KB NB 142 70; KB NB 142 92; KB NB 165 02; KB NB 165 09; KB NB 165 31; KB NB 165 92; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHLORETIN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE D; PROTEIN KINASE D INHIBITOR; PROTEIN KINASE D1; PROTEIN KINASE D2; PROTEIN KINASE D3; QUERCETIN; RESVERATROL; STAUROSPORINE; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2' (CYCLOHEXYLAMINO) 6 (PIPERAZIN 1 YL) (2,4' BIPYRIDINE) 4 CARBOXAMIDE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; BASAL CELL CARCINOMA; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RESISTANCE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; SUBCUTANEOUS TISSUE TUMOR; SURVIVAL RATE; SURVIVAL TIME; TUMOR VASCULARIZATION; CANCER THERAPY; DRUG EFFICACY; DRUG STRUCTURE;

CELL MOVEMENT; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 78649477489     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.05.003     Document Type: Review

References (128)

1. Rozengurt E., Rey O., Waldron R.T. Protein kinase D signaling. J. Biol. Chem. 2005, 280:13205-13208.
2. Waldron R.T., Iglesias T., Rozengurt E. Phosphorylation-dependent protein kinase D activation. Electrophoresis 1999, 20:382-390.
3. Zugaza J.L., Sinnett-Smith J., Van Lint J., Rozengurt E. Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transduction pathway. EMBO J. 1996, 15:6220-6230.
4. Bankaitis V.A. Cell biology. Slick recruitment to the Golgi. Science 2002, 295:290-291.
5. Cuenda A., Nebreda A.R. p38delta and PKD1: kinase switches for insulin secretion. Cell 2009, 136:209-210.
6. Ghanekar Y., Lowe M. Protein kinase D: activation for Golgi carrier formation. Trends Cell Biol. 2005, 15:511-514.
7. Jamora C., Yamanouye N., Van Lint J., Laudenslager J., Vandenheede J.R., Faulkner D.J., Malhotra V. Gbetagamma-mediated regulation of Golgi organization is through the direct activation of protein kinase D. Cell 1999, 98:59-68.
8. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., Marme D., Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J. Biol. Chem. 1993, 268:9194-9197.
9. Liljedahl M., Maeda Y., Colanzi A., Ayala I., Van Lint J., Malhotra V. Protein kinase D regulates the fission of cell surface destined transport carriers from the trans-Golgi network. Cell 2001, 104:409-420.
10. Yeaman C., Ayala M.I., Wright J.R., Bard F., Bossard C., Ang A., Maeda Y., Seufferlein T., Mellman I., Nelson W.J., Malhotra V. Protein kinase D regulates basolateral membrane protein exit from trans-Golgi network. Nat. Cell Biol. 2004, 6:106-112.
11. Bossard C., Bresson D., Polishchuk R.S., Malhotra V. Dimeric PKD regulates membrane fission to form transport carriers at the TGN. J. Cell Biol. 2007, 179:1123-1131.
12. Sumara G., Formentini I., Collins S., Sumara I., Windak R., Bodenmiller B., Ramracheya R., Caille D., Jiang H., Platt K.A., Meda P., Aebersold R., Rorsman P., Ricci R. Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. Cell 2009, 136:235-248.
13. Woods A.J., White D.P., Caswell P.T., Norman J.C. PKD1/PKCmu promotes alphavbeta3 integrin recycling and delivery to nascent focal adhesions. EMBO J. 2004, 23:2531-2543.
14. Prigozhina N.L., Waterman-Storer C.M. Protein kinase D-mediated anterograde membrane trafficking is required for fibroblast motility. Curr. Biol. 2004, 14:88-98.
15. Matthews S.A., Liu P., Spitaler M., Olson E.N., McKinsey T.A., Cantrell D.A., Scharenberg A.M. Essential role for protein kinase D family kinases in the regulation of class II histone deacetylases in B lymphocytes. Mol. Cell. Biol. 2006, 26:1569-1577.
16. Marklund U., Lightfoot K., Cantrell D. Intracellular location and cell context-dependent function of protein kinase D. Immunity 2003, 19:491-501.
17. Medeiros R.B., Dickey D.M., Chung H., Quale A.C., Nagarajan L.R., Billadeau D.D., Shimizu Y. Protein kinase D1 and the beta 1 integrin cytoplasmic domain control beta 1 integrin function via regulation of Rap1 activation. Immunity 2005, 23:213-226.
18. Storz P. Mitochondrial ROS-radical detoxification, mediated by protein kinase D. Trends Cell Biol. 2007, 17:13-18.
19. Storz P., Doppler H., Johannes F.J., Toker A. Tyrosine phosphorylation of protein kinase D in the pleckstrin homology domain leads to activation. J. Biol. Chem. 2003, 278:17969-17976.
20. Waldron R.T., Rozengurt E. Oxidative stress induces protein kinase D activation in intact cells. Involvement of Src and dependence on protein kinase C. J. Biol. Chem. 2000, 275:17114-17121.
21. Storz P., Doppler H., Toker A. Protein kinase D mediates mitochondrion-to-nucleus signaling and detoxification from mitochondrial reactive oxygen species. Mol. Cell. Biol. 2005, 25:8520-8530.
22. Altschmied J., Haendeler J. A new kid on the block: PKD1: a promising target for antiangiogenic therapy?. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1689-1690.
23. Ha C.H., Jin Z.G. Protein kinase D1, a new molecular player in VEGF signaling and angiogenesis. Mol. Cells 2009, 28:1-5.
24. McKinsey T.A. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc. Res. 2007, 73:667-677.
25. Haworth R.S., Avkiran M. Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol. 2001, 62:1647-1651.
26. Wong C., Jin Z.G. Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J. Biol. Chem. 2005, 280:33262-33269.
27. Ha C.H., Wang W., Jhun B.S., Wong C., Hausser A., Pfizenmaier K., McKinsey T.A., Olson E.N., Jin Z.G. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J. Biol. Chem. 2008, 283:14590-14599.
28. Ha C.H., Jhun B.S., Kao H.Y., Jin Z.G. VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1782-1788.
29. Wang S., Li X., Parra M., Verdin E., Bassel-Duby R., Olson E.N. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7738-7743.
30. Vega R.B., Harrison B.C., Meadows E., Roberts C.R., Papst P.J., Olson E.N., McKinsey T.A. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol. 2004, 24:8374-8385.
31. Fielitz J., Kim M.S., Shelton J.M., Qi X., Hill J.A., Richardson J.A., Bassel-Duby R., Olson E.N. Requirement of protein kinase D1 for pathological cardiac remodeling. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3059-3063.
32. Harrison B.C., Kim M.S., van Rooij E., Plato C.F., Papst P.J., Vega R.B., McAnally J.A., Richardson J.A., Bassel-Duby R., Olson E.N., McKinsey T.A. Regulation of cardiac stress signaling by protein kinase d1. Mol. Cell. Biol. 2006, 26:3875-3888.
33. Sharlow E.R., Giridhar K.V., LaValle C.R., Chen J., Leimgruber S., Barrett R., Bravo-Altamirano K., Wipf P., Lazo J.S., Wang Q.J. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J. Biol. Chem. 2008, 283:33516-33526.
34. Monovich L., Vega R.B., Meredith E., Miranda K., Rao C., Capparelli M., Lemon D.D., Phan D., Koch K.A., Chapo J.A., Hood D.B., McKinsey T.A. A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase. FEBS Lett. 2010, 584:631-637.
35. Harikumar K.B., Kunnumakkara A.B., Ochi N., Tong Z., Deorukhkar A., Sung B., Kelland L., Jamieson S., Sutherland R., Raynham T., Charles M., Bagherazadeh A., Foxton C., Boakes A., Farooq M., Maru D., Diagaradjane P., Matsuo Y., Sinnett-Smith J., Gelovani J., Krishnan S., Aggarwal B.B., Rozengurt E., Ireson C.R., Guha S. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol. Cancer Ther. 2010, 9:1136-1146.
36. Johannes F.J., Prestle J., Eis S., Oberhagemann P., Pfizenmaier K. PKCu is a novel, atypical member of the protein kinase C family. J. Biol. Chem. 1994, 269:6140-6148.
37. Valverde A.M., Sinnett-Smith J., Van Lint J., Rozengurt E. Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8572-8576.
38. Sturany S., Van Lint J., Muller F., Wilda M., Hameister H., Hocker M., Brey A., Gern U., Vandenheede J., Gress T., Adler G., Seufferlein T. Molecular cloning and characterization of the human protein kinase D2. A novel member of the protein kinase D family of serine threonine kinases. J. Biol. Chem. 2001, 276:3310-3318.
39. Hayashi A., Seki N., Hattori A., Kozuma S., Saito T. PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu. Biochim. Biophys. Acta 1999, 1450:99-106.
40. Wang Q.J. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol. Sci. 2006, 27:317-323.
41. Iglesias T., Rozengurt E. Protein kinase D activation by mutations within its pleckstrin homology domain. J. Biol. Chem. 1998, 273:410-416.
42. Waldron R.T., Rozengurt E. Protein kinase C phosphorylates protein kinase D activation loop Ser744 and Ser748 and releases autoinhibition by the pleckstrin homology domain. J. Biol. Chem. 2003, 278:154-163.
43. Matthews S.A., Rozengurt E., Cantrell D. Characterization of serine 916 as an in vivo autophosphorylation site for protein kinase D/protein kinase Cmu. J. Biol. Chem. 1999, 274:26543-26549.
44. Jacamo R., Sinnett-Smith J., Rey O., Waldron R.T., Rozengurt E. Sequential protein kinase C (PKC)-dependent and PKC-independent protein kinase D catalytic activation via Gq-coupled receptors: differential regulation of activation loop Ser(744) and Ser(748) phosphorylation. J. Biol. Chem. 2008, 283:12877-12887.
45. Storz P., Doppler H., Toker A. Protein kinase Cdelta selectively regulates protein kinase D-dependent activation of NF-kappaB in oxidative stress signaling. Mol. Cell. Biol. 2004, 24:2614-2626.
46. von Blume J., Knippschild U., Dequiedt F., Giamas G., Beck A., Auer A., Van Lint J., Adler G., Seufferlein T. Phosphorylation at Ser244 by CK1 determines nuclear localization and substrate targeting of PKD2. EMBO J. 2007, 26:4619-4633.
47. Rey O., Yuan J., Young S.H., Rozengurt E. Protein kinase C nu/protein kinase D3 nuclear localization, catalytic activation, and intracellular redistribution in response to G protein-coupled receptor agonists. J. Biol. Chem. 2003, 278:23773-23785.
48. Rey O., Sinnett-Smith J., Zhukova E., Rozengurt E. Regulated nucleocytoplasmic transport of protein kinase D in response to G protein-coupled receptor activation. J. Biol. Chem. 2001, 276:49228-49235.
49. Zugaza J.L., Waldron R.T., Sinnett-Smith J., Rozengurt E. Bombesin, vasopressin, endothelin, bradykinin, and platelet-derived growth factor rapidly activate protein kinase D through a protein kinase C-dependent signal transduction pathway. J. Biol. Chem. 1997, 272:23952-23960.
50. Matthews S.A., Pettit G.R., Rozengurt E. Bryostatin 1 induces biphasic activation of protein kinase D in intact cells. J. Biol. Chem. 1997, 272:20245-20250.
51. Rozengurt E., Sinnett-Smith J., Zugaza J.L. Protein kinase D: a novel target for diacylglycerol and phorbol esters. Biochem. Soc. Trans. 1997, 25:565-571.
52. Guha S., Rey O., Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2002, 62:1632-1640.
53. Zhukova E., Sinnett-Smith J., Rozengurt E. Protein kinase D potentiates DNA synthesis and cell proliferation induced by bombesin, vasopressin, or phorbol esters in Swiss 3T3 cells. J. Biol. Chem. 2001, 276:40298-40305.
54. Rennecke J., Rehberger P.A., Furstenberger G., Johannes F.J., Stohr M., Marks F., Richter K.H. Protein-kinase-Cmu expression correlates with enhanced keratinocyte proliferation in normal and neoplastic mouse epidermis and in cell culture. Int. J. Cancer 1999, 80:98-103.
55. Shapiro B.A., Ray S., Jung E., Allred W.T., Bollag W.B. Putative conventional protein kinase C inhibitor Godecke 6976 [12-(2-cyanoethyl)-6, 7, 12, 13-tetrahydro-13-methyl-5-oxo-5H-indolo(2, 3-a)py rrolo(3, 4-c)-carbazole] stimulates transglutaminase activity in primary mouse epidermal keratinocytes. J. Pharmacol. Exp. Ther. 2002, 302:352-358.
56. Chen J., Deng F., Singh S.V., Wang Q.J. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 2008, 68:3844-3853.
57. Trauzold A., Schmiedel S., Sipos B., Wermann H., Westphal S., Roder C., Klapper W., Arlt A., Lehnert L., Ungefroren H., Johannes F.J., Kalthoff H. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene 2003, 22:8939-8947.
58. Sinnett-Smith J., Zhukova E., Hsieh N., Jiang X., Rozengurt E. Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in Swiss 3T3 cells. J. Biol. Chem. 2004, 279:16883-16893.
59. Sinnett-Smith J., Zhukova E., Rey O., Rozengurt E. Protein kinase D2 potentiates MEK/ERK/RSK signaling, c-Fos accumulation and DNA synthesis induced by bombesin in Swiss 3T3 cells. J. Cell. Physiol. 2007, 211:781-790.
60. Van Lint J., Rykx A., Maeda Y., Vantus T., Sturany S., Malhotra V., Vandenheede J.R., Seufferlein T. Protein kinase D: an intracellular traffic regulator on the move. Trends Cell Biol. 2002, 12:193-200.
61. Wang Y., Waldron R.T., Dhaka A., Patel A., Riley M.M., Rozengurt E., Colicelli J. The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol. Cell. Biol. 2002, 22:916-926.
62. Zhang W., Zheng S., Storz P., Min W. Protein kinase D specifically mediates apoptosis signal-regulating kinase 1-JNK signaling induced by H2O2 but not tumor necrosis factor. J. Biol. Chem. 2005, 280:19036-19044.
63. Biliran H., Jan Y., Chen R., Pasquale E.B., Ruoslahti E. Protein kinase D is a positive regulator of Bit1 apoptotic function. J. Biol. Chem. 2008, 283:28029-28037.
64. Endo K., Oki E., Biedermann V., Kojima H., Yoshida K., Johannes F.J., Kufe D., Datta R. Proteolytic cleavage and activation of protein kinase C [micro] by caspase-3 in the apoptotic response of cells to 1-beta-d-arabinofuranosylcytosine and other genotoxic agents. J. Biol. Chem. 2000, 275:18476-18481.
65. Vantus T., Vertommen D., Saelens X., Rykx A., De Kimpe L., Vancauwenbergh S., Mikhalap S., Waelkens E., Keri G., Seufferlein T., Vandenabeele P., Rider M.H., Vandenheede J.R., Van Lint J. Doxorubicin-induced activation of protein kinase D1 through caspase-mediated proteolytic cleavage: identification of two cleavage sites by microsequencing. Cell. Signal. 2004, 16:703-709.
66. Doppler H., Storz P., Li J., Comb M.J., Toker A. A phosphorylation state-specific antibody recognizes Hsp27, a novel substrate of protein kinase D. J. Biol. Chem. 2005, 280:15013-15019.
67. Ding G., Sonoda H., Yu H., Kajimoto T., Goparaju S.K., Jahangeer S., Okada T., Nakamura S. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J. Biol. Chem. 2007, 282:27493-27502.
68. Hassan S., Biswas M.H., Zhang C., Du C., Balaji K.C. Heat shock protein 27 mediates repression of androgen receptor function by protein kinase D1 in prostate cancer cells. Oncogene 2009, 28:4386-4396.
69. De Kimpe L., Janssens K., Derua R., Armacki M., Goicoechea S., Otey C., Waelkens E., Vandoninck S., Vandenheede J.R., Seufferlein T., Van Lint J. Characterization of cortactin as an in vivo protein kinase D substrate: interdependence of sites and potentiation by Src. Cell. Signal. 2009, 21:253-263.
70. Watkins J.L., Lewandowski K.T., Meek S.E., Storz P., Toker A., Piwnica-Worms H. Phosphorylation of the Par-1 polarity kinase by protein kinase D regulates 14-3-3 binding and membrane association. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:18378-18383.
71. Eiseler T., Doppler H., Yan I.K., Kitatani K., Mizuno K., Storz P. Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat. Cell Biol. 2009, 11:545-556.
72. Nishita M., Tomizawa C., Yamamoto M., Horita Y., Ohashi K., Mizuno K. Spatial and temporal regulation of cofilin activity by LIM kinase and Slingshot is critical for directional cell migration. J. Cell Biol. 2005, 171:349-359.
73. Eiseler T., Doppler H., Yan I.K., Goodison S., Storz P. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res. 2009, 11:R13.
74. Lee J.W., Kwak H.J., Lee J.J., Kim Y.N., Lee J.W., Park M.J., Jung S.E., Hong S.I., Lee J.H., Lee J.S. HSP27 regulates cell adhesion and invasion via modulation of focal adhesion kinase and MMP-2 expression. Eur. J. Cell Biol. 2008, 87:377-387.
75. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
76. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
77. Qin L., Zeng H., Zhao D. Requirement of protein kinase D tyrosine phosphorylation for VEGF-A165-induced angiogenesis through its interaction and regulation of phospholipase Cgamma phosphorylation. J. Biol. Chem. 2006, 281:32550-32558.
78. Martin M., Kettmann R., Dequiedt F. Class IIa histone deacetylases: regulating the regulators. Oncogene 2007, 26:5450-5467.
79. Bowden E.T., Barth M., Thomas D., Glazer R.I., Mueller S.C. An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene 1999, 18:4440-4449.
80. Farmer P., Bonnefoi H., Becette V., Tubiana-Hulin M., Fumoleau P., Larsimont D., Macgrogan G., Bergh J., Cameron D., Goldstein D., Duss S., Nicoulaz A.L., Brisken C., Fiche M., Delorenzi M., Iggo R. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005, 24:4660-4671.
81. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
82. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J. Med. 2002, 347:1999-2009.
83. Turashvili G., Bouchal J., Baumforth K., Wei W., Dziechciarkova M., Ehrmann J., Klein J., Fridman E., Skarda J., Srovnal J., Hajduch M., Murray P., Kolar Z. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55.
84. Poola I., DeWitty R.L., Marshalleck J.J., Bhatnagar R., Abraham J., Leffall L.D. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat. Med. 2005, 11:481-483.
85. Stylli S.S., Kaye A.H., Lock P. Invadopodia: at the cutting edge of tumour invasion. J. Clin. Neurosci. 2008, 15:725-737.
86. Janssens K., De Kimpe L., Balsamo M., Vandoninck S., Vandenheede J.R., Gertler F., Van Lint J. Characterization of EVL-I as a protein kinase D substrate. Cell. Signal. 2009, 21:282-292.
87. Krause M., Dent E.W., Bear J.E., Loureiro J.J., Gertler F.B. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu. Rev. Cell Dev. Biol. 2003, 19:541-564.
88. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
89. Chicoine M.R., Silbergeld D.L. Assessment of brain tumor cell motility in vivo and in vitro. J. Neurosurg. 1995, 82:615-622.
90. Krause M., Bear J.E., Loureiro J.J., Gertler F.B. The Ena/VASP enigma. J. Cell Sci. 2002, 115:4721-4726.
91. Bear J.E., Svitkina T.M., Krause M., Schafer D.A., Loureiro J.J., Strasser G.A., Maly I.V., Chaga O.Y., Cooper J.A., Borisy G.G., Gertler F.B. Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell 2002, 109:509-521.
92. Kennett S.B., Roberts J.D., Olden K. Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. J. Biol. Chem. 2004, 279:3300-3307.
93. Palmantier R., George M.D., Akiyama S.K., Wolber F.M., Olden K., Roberts J.D. Cis-polyunsaturated fatty acids stimulate beta1 integrin-mediated adhesion of human breast carcinoma cells to type IV collagen by activating protein kinases C-epsilon and -mu. Cancer Res. 2001, 61:2445-2452.
94. Jezierska A., Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med. Sci. Monit. 2009, 15:RA32-RA40.
95. Peterburs P., Heering J., Link G., Pfizenmaier K., Olayioye M.A., Hausser A. Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res. 2009, 69:5634-5638.
96. Philip P.A. Targeted therapies for pancreatic cancer. Gastrointest. Cancer Res. 2008, 2:S16-S19.
97. K.B. Harikumar, A.B. Kunnumakkara, N. Ochi, Z. Tong, A. Deorukhkar, B. Sung, L. Kelland, S. Jamieson, R. Sutherland, T. Raynham, M. Charles, A. Bagherazadeh, C. Foxton, A. Boakes, M. Farooq, D. Maru, P. Diagaradjane, Y. Matsuo, J. Sinnett-Smith, J. Gelovani, S. Krishnan, B.B. Aggarwal, E. Rozengurt, C.R. Ireson, S. Guha, A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo, Mol Cancer Ther 9 (2010) 1136-1146.
98. Yuan J., Rozengurt E. PKD, PKD2, and p38 MAPK mediate Hsp27 serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 cells. J. Cell. Biochem. 2008, 103:648-662.
99. Berkowitz P., Hu P., Warren S., Liu Z., Diaz L.A., Rubenstein D.S. p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12855-12860.
100. Rousseau S., Houle F., Landry J., Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997, 15:2169-2177.
101. Kostenko S., Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell. Mol. Life Sci. 2009, 66:3289-3307.
102. Ciocca D.R., Calderwood S.K. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10:86-103.
103. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
104. Shirai T. Significance of chemoprevention for prostate cancer development: experimental in vivo approaches to chemoprevention. Pathol. Int. 2008, 58:1-16.
105. Jaggi M., Rao P.S., Smith D.J., Hemstreet G.P., Balaji K.C. Protein kinase C mu is down-regulated in androgen-independent prostate cancer. Biochem. Biophys. Res. Commun. 2003, 307:254-260.
106. Mak P., Jaggi M., Syed V., Chauhan S.C., Hassan S., Biswas H., Balaji K.C. Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. Biochem. Biophys. Res. Commun. 2008, 373:618-623.
107. Jaggi M., Chauhan S.C., Du C., Balaji K.C. Bryostatin 1 modulates beta-catenin subcellular localization and transcription activity through protein kinase D1 activation. Mol. Cancer Ther. 2008, 7:2703-2712.
108. Jaggi M., Rao P.S., Smith D.J., Wheelock M.J., Johnson K.R., Hemstreet G.P., Balaji K.C. E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res. 2005, 65:483-492.
109. Syed V., Mak P., Du C., Balaji K.C. Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1. J. Cell. Biochem. 2008, 104:82-95.
110. Du C., Jaggi M., Zhang C., Balaji K.C. Protein kinase D1-mediated phosphorylation and subcellular localization of beta-catenin. Cancer Res. 2009, 69:1117-1124.
111. Sarker D., Reid A.H., Yap T.A., de Bono J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 2009, 15:4799-4805.
112. Nelson E.C., Evans C.P., Mack P.C., Devere-White R.W., Lara P.N. Inhibition of Akt pathways in the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007, 10:331-339.
113. Wong C.S., Strange R.C., Lear J.T. Basal cell carcinoma. BMJ 2003, 327:794-798.
114. Ristich V.L., Bowman P.H., Dodd M.E., Bollag W.B. Protein kinase D distribution in normal human epidermis, basal cell carcinoma and psoriasis. Br. J. Dermatol. 2006, 154:586-593.
115. Kim M., Jang H.R., Kim J.H., Noh S.M., Song K.S., Cho J.S., Jeong H.Y., Norman J.C., Caswell P.T., Kang G.H., Kim S.Y., Yoo H.S., Kim Y.S. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis 2008, 29:629-637.
116. Lee H.J., Yang H.K., Ahn Y.O. Gastric cancer in Korea. Gastric Cancer 2002, 5:177-182.
117. Paolucci L., Rozengurt E. Protein kinase D in small cell lung cancer cells: rapid activation through protein kinase C. Cancer Res. 1999, 59:572-577.
118. Kovalevska L.M., Yurchenko O.V., Shlapatska L.M., Berdova G.G., Mikhalap S.V., Van Lint J., Sidorenko S.P. Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymphomas. Exp. Oncol. 2006, 28:225-230.
119. Gschwendt M., Dieterich S., Rennecke J., Kittstein W., Mueller H.J., Johannes F.J. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996, 392:77-80.
120. Stewart J.R., Christman K.L., O'Brian C.A. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem. Pharmacol. 2000, 60:1355-1359.
121. Aggarwal B.B., Bhardwaj A., Aggarwal R.S., Seeram N.P., Shishodia S., Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004, 24:2783-2840.
122. Gschwendt M., Kittstein W., Johannes F.J. Differential effects of suramin on protein kinase C isoenzymes. A novel tool for discriminating protein kinase C activities. FEBS Lett. 1998, 421:165-168.
123. E. Torres-Marquez, J. Sinnett-Smith, S. Guha, R. Kui, R.T. Waldron, O. Rey, E. Rozengurt, CID755673 enhances mitogenic signaling by phorbol esters, bombesin and EGF through a protein kinase D-independent pathway, Biochem Biophys Res Commun 391 (2010) 63-68.
124. LaValle C.R., Bravo-Altamirano K., Giridhar K.V., Chen J., Sharlow E.R., Lazo J.S., Wipf P., Wang Q.J. Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chemical Biology 2010, 10:5.
125. T.M. Raynham, T.R. Hammonds, J.H. Gillatt, M.D. Charles, G.A. Pave, C.H. Foxton, J.L. Carr, N.S. Mistry, Amino-Ethyl-Amino-Aryl (AEAA) Compounds and Their Use, in: WIPO (Ed.), 2007.
126. T.M. Raynham, T.R. Hammonds, M.D. Charles, G.A. Pave, C.H. Foxton, W.P. Blackaby, A.P. Stevens, C.T. Ekwuru, Pyridine Benzamides and Pyrazine Benzamides Used as PKD Inhibitors in: WIPO (Ed.), 2008.
127. R. Singh, H. Li, H. Zhao, D.G. Payan, R. Kolluri, K. Tso, J. Ramphal, S. Gu, Cyclic Amine Substituted Pyrimidinediamines as PKC Inhibitors, in: WIPO (Ed.), 2009.
128. van Montfort R.L., Workman P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol. 2009, 27:315-328.